NewsBenzingaMorgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27 Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27 Benzinga 2026.10.13 15:33 (GMT+0) Open on Benzinga Other news Wall Street Brunch: SpaceX, Tesla, Meta On The Earnings Card (undefined:SPCX) Fifth Third, Steel Dynamics Earnings Test Bank Trends And Steel Demand UTES Vs. UTG: Why I Prefer The ETF As Rates Rise. (NYSE:UTG) Jefferies Makes a Bold $85 Call on Netflix Stock Earnings Preview: What to Expect From Mosaic’s Report Gartner’s Q3 2026 Earnings: What to Expect
